Carotid atherosclerosis accounts for approximately 10% of ischemic stroke cases. Multifaceted medical therapy reduces the risk of stroke in patients with carotid stenosis. Revascularization with endarterectomy or stenting can benefit select patients. In recent years, new information has been obtained regarding optimal selection of revascularization candidates.
In this update, we shall review current recommendations for management of symptomatic and asymptomatic internal carotid artery (ICA) stenosis.
In addition, we shall identify new clinical correlates in "asymptomatic" patients and review the impact of contemporary medical therapy on stroke rates for carotid stenosis patients. Finally, we will discuss current clinical trials regarding ICA stenosis.
PREVALENCE AND PREDICTORS OF CAROTID STENOSIS AND STROKE RISK
In the Framingham Heart Study, the degree of carotid stenosis was predicted by common baseline vascular risk factors such as older age, cigarette smoking, systolic blood pressure, and total cholesterol (1) . Patients with asymptomatic ICA stenosis of 60% to 99%
have an annual risk of stroke, based on 1990s medical therapy, of 2% to 2.5% per year (2, 3) . On the other hand, symptomatic carotid stenosis over 70% carries an annual stroke risk of 10% to 15%, based on 1990s medical therapy (4) .
The prevalence of severe ($70%) asymptomatic stenosis in the general population varies according to age and baseline risk factors. In a meta-analysis of 4 individual participant longitudinal studies, the prevalence of severe stenosis ranged from 0% to 3.1% in various age and sex groups (5) . Among men, severe stenosis was present in 0.1% (95% confidence interval
[CI]: 0% to 0.3%) of subjects <50 years of age and in 3.1% (CI: 1.7% to 5.3%) of those >80 years of age.
Among women, the prevalence of severe stenosis was minimal (95% CI: 0% to 0.2%) in subjects <50 years of age and 0.9% (95% CI: 0.3% to 2.4%) in women >80 years of age. The same investigators developed a predictive instrument for identifying the presence of severe stenosis. Elements of the score are provided in Table 1 .
Although some advocate screening higher-risk patients with coronary artery disease or peripheral arterial disease for ICA stenosis, the evidence to support this practice is limited. The US Preventive Services Task Force reviewed studies pertaining to population screening through 2014 and concluded that routine screening of the general population to detect asymptomatic ICA stenosis is not warranted (6) . Among the reasons for this recommendation were the following: 1) concern that low complication rates after carotid endarterectomy (CEA) and CAS could not be replicated in community practice; 2) lack of studies comparing CAS to optimal medical therapy; 3) falling rates of stroke with contemporary medical therapy; and 4) significant generation of "false positives" with duplex ultrasound as the screening tool. patients with a prior stroke or TIA (9) . In a subgroup analysis of patients with carotid stenosis, 1,007 patients had a mean stenosis of 51% (10) . In the patients given atorvastatin, low-density lipoprotein (LDL) was lowered from 132 mg/dl at baseline to an average of 70 mg/dl during trial follow-up. In the patients given placebo, LDL decreased from 133 to 130 mg/dl. The atorvastatin-treated patients had a 33% reduction in any stroke, a 43% reduction in coronary events, and a 56% reduction in later carotid revascularization pro- Table 2 ). There was also no difference in the risk of major stroke during the 4-year study period (11% for CAS vs. 8% for CEA; p ¼ 0.52).
CURRENT EVIDENCE FOR THE TREATMENT OF CAROTID STENOSIS
Patients >70 years of age fared better with CEA, whereas patients younger than 70 years of age tended to fare better with CAS (p ¼ 0.02 for interaction) (13, 14) . A similar finding was noted in a pre-planned meta-analysis of 3 European studies (15) . The event rate for any stroke or death in the patients treated with CEA was 5.7% in subjects younger than 70 years At 10 years, the CAS event rate compared with the CEA group was 11.5% versus 7.6% (HR: 1.70; 95% CI:
0.95 to 3.06; p ¼ 0.07). There were no differences in ipsilateral stroke risks in the 2 treatment groups beyond the procedural period. Thus, CEA had a small advantage during long-term follow-up.
On the basis of these data, multidisciplinary panels have provided the recommendations given in the following sections (8, 11, 20) .
SYMPTOMATIC STENOSIS.
1. For patients with a TIA or stroke within the past 6 months and ipsilateral severe stenosis (70% to 99%), CEA is recommended if the perioperative stroke/death rate is estimated to be <6% (Class I, Level of Evidence: A).
2. When the degree of stenosis is <50%, CEA and CAS are not recommended (Class III, Level of Evidence: A).
3. When revascularization is indicated, it is reasonable to perform surgery within 2 weeks rather than delay surgery (Class IIa, Level of Evidence: B).
CAS is indicated as an alternative to CEA if the anticipated perioperative stroke/death rate is <6%
(Class IIa, Level of Evidence: B).
It is reasonable to consider patient age in choosing
between CEA and CAS (Class IIa, Level of Evidence: B).
ASYMPTOMATIC PATIENTS. 
SELECTION OF REVASCULARIZATION METHOD
CEA is a well-established procedure with several decades of experience in the community. The complications of CEA are well described, including complications pertaining to the brain, systemic complications, and local hazards. The primary neurological complications in the brain are ischemic and hemorrhagic stroke. Symptomatic patients have a higher stroke risk than asymptomatic subjects (21) . With regard to systemic complications, the most serious is MI.
As mentioned above, in CREST, the periprocedural MI CAS is a more recent revascularization procedure, the use of which has increased rapidly in community practice (23) . For CAS, in addition to the hazards of advanced age described above, the complication rate Another procedure-specific hazard of CAS is periprocedural bradycardia or hypotension. In some instances, bradycardia or hypotension can be prolonged and lead to intensive care unit admission and increased periprocedural morbidity (25) . Hypotension can also follow CEA in up to 12% to 27% of patients (26, 27) . For the symptomatic patient, With regard to silent strokes, an older study using computed tomography scans found that 19% of patients with asymptomatic stenosis had at least 1 ischemic lesion, with 68% being ipsilateral to the carotid stenosis (29) . A more recent systematic review were more likely to have carotid stenosis than those without progressive cognitive decline (32) . These findings suggest a potential synergistic role between Alzheimer neuropathology and carotid stenosis.
Some limitations of these studies deserve mention.
First, there was no documentation of neuroimaging
findings in these studies. It is possible that the patients with cognitive impairment were those with Table 2 . Table 4 . The primary endpoint occurred in 12% of patients at 1 year, or approximately 50% less
Chaturvedi and Sacco A systematic analysis also documented falling rates of stroke in patients with asymptomatic ICA stenosis (47) .
Two important demographic subgroups to consider in treatment decisions for ACS are women and the elderly. In a combined analysis of ACAS and ACST, it was found that men with ACS had a 51% relative risk reduction in the rate of stroke, whereas women did not have a reduction in stroke (48) . In plaque analysis studies, it has been noted that women have lower macrophage staining in carotid plaques and more smooth muscle, which provides for an overall "more stable" plaque than seen in men (49) . Because women were underrepresented in previous carotid stenosis trials, some have called for a future clinical trial dedicated to women with carotid stenosis (35, 50) .
With regard to the elderly, patients >80 years of age were not enrolled in ACAS. There was no upper age limit in the ACST, and therefore, the ACST has the largest clinical trial cohort of patients >75 years of age. In this group, there was no definite benefit seen with CEA in patients >75 years of age, although the study was not powered to examine this subgroup.
Because elderly patients have a reduced life patients >75 years of age will likely be more appropriate for the CEA portion of the study because of the higher complication rate with CAS in the elderly.
A trial being conducted predominantly in Germany and Austria (SPACE 2) has a similar design, with 2 parallel studies in patients with asymptomatic stenosis (53).
The only current study to include symptomatic patients is the European Carotid Surgery Trial 2 (ECST 2).
Symptomatic patients are evaluated with the carotid risk score (http://www.stroke.ox.ac.uk/model/form1.html),
and if the estimated stroke risk is <3% per year, then they may be enrolled in the study, which will compare OMT alone versus OMT plus carotid revascularization. Tables 2 and 5. 
CONCLUSIONS

